Comparative Pharmacology
Head-to-head clinical analysis: ALEVE D SINUS COLD versus MELOXICAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALEVE D SINUS COLD versus MELOXICAM.
ALEVE-D SINUS & COLD vs MELOXICAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor agonism in the nasal mucosa.
Selective inhibitor of cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and inflammation.
Naproxen 220 mg (as naproxen sodium) and pseudoephedrine HCl 120 mg orally every 12 hours; maximum 2 doses per 24 hours.
7.5-15 mg orally once daily; maximum 15 mg/day. For osteoarthritis, rheumatoid arthritis: 7.5 mg once daily, may increase to 15 mg/day if needed. For juvenile rheumatoid arthritis, weight-based dosing.
None Documented
None Documented
Clinical Note
moderateMeloxicam + Gatifloxacin
"Meloxicam may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateMeloxicam + Rosoxacin
"Meloxicam may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateMeloxicam + Levofloxacin
"Meloxicam may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateMeloxicam + Trovafloxacin
"Meloxicam may increase the neuroexcitatory activities of Trovafloxacin."
Naproxen: 12-17 hours (clinical: twice daily dosing); pseudoephedrine: 4-6 hours (clinical: every 4-6 hours).
Terminal elimination half-life: 15–20 hours. Clinical context: Allows once-daily dosing; steady-state achieved in 3–5 days.
Renal elimination: naproxen ~95% (mostly as unconjugated naproxen and 6-O-desmethyl naproxen), pseudoephedrine ~70-90% unchanged. Biliary/fecal: minor (<5% for each).
Approximately 50% renal excretion of unchanged drug and metabolites; 50% fecal excretion via bile. Renal elimination accounts for ~5% unchanged meloxicam; the remainder as metabolites (primarily oxidative and glucuronide conjugates).
Category C
Category D/X
NSAID/Decongestant Combination
NSAID